Latest news with #SLIT
Metro
01-05-2025
- Sport
- Metro
Premier League's down year hints at trouble ahead
Look, this may be the earliest the winners and losers of the Premier League have ever been decided but I maintain the league itself is still a laugh. Plus, given 11 English sides could theoretically qualify for Europe next season – see, United, you are still a big team! – there is still something in it for the majority. We talked about Liverpool last week: their title-winning moment at Anfield and everything that came after was incredible to witness. Their players deserved to enjoy it with the fans after the isolation of 2020's breakthrough win, and their focus on the collective nature of the achievement was heartwarming. This week, let's take a look at the other end of what's been decided: the bottom of the table. Southampton, Leicester and Ipswich Town have packed their trunks and said goodbye to the circus. This is the second consecutive season where all three promoted teams have been relegated. Given a major part of what makes English professional football an improvement on any American alternative is the openness of the league system, this feels as if it is a real problem. After Wrexham's third straight promotion, co-owner Rob McElhenney confirmed Premier League football is the target. Why not, he said, when the football pyramid here is set up to make the pinnacle possible. The demise of Luton, Sheffield United and Burnley last season and now the trio no one is calling SLIT would seem to argue against this theory. Or at least – yes you can get there, but you are set up to fail. The reason this has been such a live subject is because all promoted teams getting relegated is something that did not happen in the first 99 years of the English top flight, and has only happened three times since. Two of those times are in the last two years. Given how clear SLIT's plight has been from the very early stages of the season, and given Southampton are still sitting on the record lowest points total, the situation seems significant. Competitive relegation and promotion is our heritage! Something must be done! It is clear that dominating the money leagues makes you nearly untouchable in the Premier League. Six teams have been ever-present since founding. Only seven clubs have won the title in 33 years. The gap between resources in the Championship and the top division is growing. Total revenue in the second tier in the 2022-23 season was 12% of the Premier League's, with the clubs receiving parachute payments taking the lion's share of that. But two years is not a trend. There were specific challenges at Leicester that hamstrung their season. Leicester is an atypical club given it's one of the seven Premier League winners but is also a yo-yo club in the truest sense of the term. The impact of the tragic death of their visionary chairman seven years ago is ongoing and may make their challenges insoluble in current form. More Trending Southampton's challenges are similar, although from different cause. Ipswich's long absence from the top flight and rapid rise has meant they are not yet a club ready for the rigours of the Premier League. Will Leeds and Burnley fare better next year? They could look to Nottingham Forest for inspiration – a side finishing 17th last season who have a strong chance of being in the Champions League next year – but neither Forest's success nor the repeated relegation crew are evidence that change is needed. Not just yet, anyway. But file this away for this time next year, when we may need to talk. MORE: Chelsea Women clinch WSL title for sixth season in a row with win over Man Utd MORE: Barcelona ace Lamine Yamal told he is still only the 'third-best player' in the world MORE: Mikel Arteta sent sack warning by Arsenal legend Jens Lehmann
Yahoo
14-04-2025
- Health
- Yahoo
Aptar Digital Health Reports Positive Impact of iPUMP® on Sublingual Liquid Allergen Immunotherapy Adherence
CRYSTAL LAKE, Ill., April 14, 2025--(BUSINESS WIRE)--Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, today announces the positive results from the SPEED1 survey, showcasing the impact of the iPUMP® connected assistant on adherence to Stallergenes Greer's sublingual liquid immunotherapy (SLIT). The results will be presented by Stallergenes Greer, a global leader in allergy therapeutics and long-standing partner of Aptar Digital Health, at the upcoming CFA congress (Congrès Francophone d'Allergologie) in Paris, France from April 15 to 18, 2025. The SPEED survey showed a 15% increase in treatment adherence for patients using iPUMP®. Moreover, for children aged between 5 and 12 years, parental involvement in treatment administration dropped from 50% to 28% over three months, while the proportion of children independently taking their medication rose from 24% to 58%. Notably, 90% of parents felt reassured by the connected assistant, with half of them feeling completely at ease with treatment administration, compared to 36% of respondents in the non-iPUMP® group. iPUMP®, developed in conjunction with Stallergenes Greer, supports adherence to personalized SLIT treatments by helping to ensure patients adopt the correct dosing technique, duration and frequency of treatment. This innovative and easy-to-use tool is connected to a companion mobile application and provides direct access to the personalized treatment protocol prescribed to each patient by their physician. Launched in February 2023 in France, it has been used by over 9,000 patients to date. iPUMP® helps support patients in improving treatment adherence to optimize effectiveness while offering a history-tracking function for precise medication monitoring. By supporting Stallergenes Greer in their mission to empower individuals and improve treatment outcomes, Aptar Digital Health fosters its go-to partner position in the pharmaceutical industry for the development and operation of digital health and connected solutions. Elena Rizova, Chief Medical Officer at Stallergenes Greer, stated, "Findings of the SPEED survey underscore the role of connected health solutions in improving both treatment adherence and patient confidence, which are key elements in achieving successful therapeutic outcomes." She added, "Innovation is at the heart of what we do and iPUMP®, by catering to the needs expressed by patients and healthcare professionals, meets their expectations and provides a solution to enhance treatment management and overall allergy care." Marcus Bates, VP Business Development & Global Head of Respiratory at Aptar Digital Health, commented, "The strong results of the SPEED survey pave the way for wider adoption of digital and connected solutions for allergy management, enabling new patients to access a simple, easy-to-use solution that can help track adherence and stay engaged to achieve better health outcomes." The SPEED survey results establish a strong foundation for broader adoption of iPUMP®, supporting Stallergenes Greer's commitment to innovate for the benefit of patients, caregivers and the medical community. About Aptar Digital Health Aptar Pharma's Digital Health division is part of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar Digital Health creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions. Amplified by an industry-leading portfolio of products and solutions, Aptar Digital Health's offering combines mobile and web apps, Software-as-Medical-Device, connected drug delivery systems, advanced data analysis services, and patient onboarding and training solutions to actively empower patients and create a positive treatment journey. Aptar is headquartered in Crystal Lake, Illinois and has more than 13,000 dedicated employees in 20 countries. For more information, visit and About Stallergenes Greer Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. For more information, visit 1 The SPEED real-life study was conducted by AplusA for Stallergenes Greer between May 29 and November 29, 2024. This online questionnaire, aimed at measuring the impact perceived by patients after three months of treatment with allergen immunotherapy (AIT) using Aptar Digital Health's iPUMP® connected assistant, included 104 pediatric patients over 5 years of age and 77 adolescent and adult patients over 13 years of age. View source version on Contacts Media Contact: Ciara JacksonAptar Pharma+49 151 1951
